Raynaud Phenomenon
Return to Library
|
Free Raynaud Phenomenon Articles |
|
|
|
|
Research from S.N. Lambova and co-authors yields new data on raynaud phenomenon therapy
2009 JUN 29 - (NewsRx.com) -- Investigators publish new data in the report 'New lines in therapy of Raynaud's phenomenon.' According to recent research from Plovdiv, Bulgaria, "Current knowledge about the pathogenesis of Raynaud's phenomenon (RP) results in novel approaches for therapy. Vasospasm without endothelial damage is thought to be the main cause for primary RP." "The pathogenesis of secondary forms of RP is supposed to be initiated primary by endothelial damage. The aim of the review is to present main groups of medications as well as non-pharmacological regimen, that are used for the treatment of RP. The necessity of immediate assessment and treatment in severe forms of the disease with digital ulcers is highlighted. The mild forms of primary RP can be controlled by non-pharmacologic approaches. If the effect is insufficient, medications of first choice are calcium channel blockers. In the severe forms of the disorder, intravenous infusion of prostacyclin as well as endothelin-1 receptor antagonists and specific inhibitors of phosphodiesterase-5 are the treatment of choice," wrote S.N. Lambova and colleagues, . The researchers concluded: "Treatment in the future may include selective blockers of alpha-2c adrenergic receptors, inhibitors of protein tyrosine kinase and Rho-kinase, as well as calcitonin gene-related peptide." Lambova and colleagues published their study in Rheumatology International (New lines in therapy of Raynaud's phenomenon. Rheumatology International, 2009;29(4):355-63). For additional information, contact S.N. Lambova, Clinic of Rheumatology, Medical University, Plovdiv, Bulgaria. Publisher contact information for the journal Rheumatology International is: Oxford University Press, Great Clarendon St., Oxford OX2 6DP, England. Keywords: Bulgaria, Plovdiv, Raynaud Phenomenon Therapy, Drug Development, Immunology, Pharmaceuticals, Pharmacological, Raynaud Phenomenon, Rheumatology, Therapy, Treatment. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2009, Biotech Business Week via NewsRx.com.
|
